Actelion, being bought by J&J, says full year core net income rose 27 percent
Swiss drugmaker Actelion's 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH), it said on Tuesday. Core net income rose to 881 million Swiss francs ($877.8 million) from 693 million francs in the previous year, the company said in a statement. Sales rose 18 percent to 2.42 billion francs, in line with the 2.41 billion francs expected in a Reuters poll.
The post Actelion, being bought by J&J, says full year core net income rose 27 percent appeared first on
Health News Headlines - Yahoo News.
Previous Article
Next ArticleRelated Posts
If You Want to Die Young, Move to Rural America 
Gun Violence Draining Public Health Resources 
Opioids vs. Marijuana: Which Is More Dangerous? 
A Sperm Test You Can Do at Home With a Smartphone 
How Poor Diet Raises Your Risk of Dying from Heart Disease 
Movie ‘Split’ Does Harm to People with Dissociative Identity Disorder, Experts Say 
Annual Tobacco Report Highlights Anti-Smoking Measures 
Procedure May Provide Map for AFib Treatment